COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Frequently asked questions
What sector does COMPASS Pathways plc (CMPS) operate in?
COMPASS Pathways plc belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is COMPASS Pathways plc (CMPS) current stock price?
As of the latest data, COMPASS Pathways plc stock price is $13.90, with a previous close of $13.72. COMPASS Pathways plc gained $0.18 in the last trading session, representing a 1.31% increase.
What is COMPASS Pathways plc (CMPS) current market capitalization?
COMPASS Pathways plc market cap is approximately 1.88 billion.
What is COMPASS Pathways plc (CMPS) Earnings Per Share (EPS)?
The trailing EPS is -$3.79, and the forward EPS is -$1.53.
What is COMPASS Pathways plc (CMPS) EBITDA?
COMPASS Pathways plc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -251.98 million.
Does COMPASS Pathways plc (CMPS) pay dividends?
No. COMPASS Pathways plc does not pay a dividend.
What is COMPASS Pathways plc (CMPS) beta (volatility) score?
COMPASS Pathways plc has a beta of 2.531, indicating very high volatility compared to the market.
